1. Home
  2. MGX vs TMQ Comparison

MGX vs TMQ Comparison

Compare MGX & TMQ Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • MGX
  • TMQ
  • Stock Information
  • Founded
  • MGX 2018
  • TMQ 2004
  • Country
  • MGX United States
  • TMQ Canada
  • Employees
  • MGX N/A
  • TMQ N/A
  • Industry
  • MGX
  • TMQ Precious Metals
  • Sector
  • MGX
  • TMQ Basic Materials
  • Exchange
  • MGX NYSE
  • TMQ Nasdaq
  • Market Cap
  • MGX 62.1M
  • TMQ 226.7M
  • IPO Year
  • MGX 2024
  • TMQ N/A
  • Fundamental
  • Price
  • MGX $2.08
  • TMQ $1.89
  • Analyst Decision
  • MGX Strong Buy
  • TMQ
  • Analyst Count
  • MGX 4
  • TMQ 0
  • Target Price
  • MGX $13.00
  • TMQ N/A
  • AVG Volume (30 Days)
  • MGX 916.2K
  • TMQ 613.8K
  • Earning Date
  • MGX 08-13-2025
  • TMQ 07-10-2025
  • Dividend Yield
  • MGX N/A
  • TMQ N/A
  • EPS Growth
  • MGX N/A
  • TMQ N/A
  • EPS
  • MGX N/A
  • TMQ N/A
  • Revenue
  • MGX $45,263,000.00
  • TMQ N/A
  • Revenue This Year
  • MGX N/A
  • TMQ N/A
  • Revenue Next Year
  • MGX $11.75
  • TMQ N/A
  • P/E Ratio
  • MGX N/A
  • TMQ N/A
  • Revenue Growth
  • MGX N/A
  • TMQ N/A
  • 52 Week Low
  • MGX $1.23
  • TMQ $0.47
  • 52 Week High
  • MGX $5.49
  • TMQ $2.09
  • Technical
  • Relative Strength Index (RSI)
  • MGX 62.36
  • TMQ 71.19
  • Support Level
  • MGX $2.04
  • TMQ $1.30
  • Resistance Level
  • MGX $2.47
  • TMQ $2.02
  • Average True Range (ATR)
  • MGX 0.18
  • TMQ 0.12
  • MACD
  • MGX 0.07
  • TMQ 0.05
  • Stochastic Oscillator
  • MGX 61.76
  • TMQ 65.97

About MGX METAGENOMI INC

Metagenomi Inc is a genetic medicines company committed to developing curative therapeutics for patients using its proprietary, comprehensive metagenomics-derived genome editing toolbox. The genome editing toolbox includes systems for making small edits such as programmable nucleases, base editors, small RNA-mediated integration systems (RIGS), as well as large gene integration systems including large template RIGS and CRISPR-associated transposases (CASTs). The company is focused on its vivo gene editing for its wholly-owned pipeline while pursuing technology out licensing for ex vivo cell therapy. Its pipeline includes product candidates aimed at addressing disorders like Hemophilia A (through MGX-001), Refractory Hypertension, Cardiovascular diseases, and Wilson's disease, among others.

About TMQ Trilogy Metals Inc.

Trilogy Metals Inc is an exploration stage company engaged in mineral exploration. The company focuses on exploring and developing its mineral resource properties, which include the Upper Kobuk Mineral Projects (UKMP or UKMP Projects), in the Ambler mining district located in Alaska, the United States. Its properties include the Arctic copper-zinc-gold-silver project and other mineralized targets within a volcanogenic massive sulfide belt, and it also has a bornite carbonate-hosted copper project.

Share on Social Networks: